Author:
Wang Gen-He,Wu Peng-Fei,Zhang Long-Hui,Fang Ping,Chen Yong,Zuo Gang,Wu Yi-Qing,Wang Shu-Hong,Sun Guo-Ping
Funder
Science and Technology Project
Subject
Cell Biology,Pathology and Forensic Medicine
Reference21 articles.
1. Stewart BW, Wild CP, editors. World Cancer Report 2014. International Agency for Research on Cancer; 2014.
2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012
3. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011
4. Reciprocal and complementary role of MET amplification and EGFR T790 M mutation in acquired resistance to kinase inhibitors in lung cancer;Suda;Clin. Cancer Res.,2010
5. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790 M mutation;Rho;Mol. Cancer Ther.,2010
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献